Skip to search boxSkip to navigationSkip to main content

Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus

  • Michael A. James
    ,
  • Weidong Wen
    ,
  • Yian Wang
    ,
  • Lauren A. Byers
    ,
  • John V. Heymach
    ,
*Corresponding author for this work
  • Medical College of Wisconsin
    ,
  • Washington University St. Louis
    ,
  • University of Texas Health Science Center at Houston
    ,
  • University of Texas Southwestern Medical Center
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Cleft Lip and Palate Transmembrane Protein 1-Like (CLPTM1L), resides in a region of chromosome 5 for which copy number gain has been found to be the most frequent genetic event in the early stages of non-small cell lung cancer (NSCLC). This locus has been found by multiple genome wide association studies to be associated with lung cancer in both smokers and non-smokers. CLPTM1L has been identified as an overexpressed protein in human ovarian tumor cell lines that are resistant to cisplatin, which is the only insight thus far into the function of CLPTM1L. Here we find CLPTM1L expression to be increased in lung adenocarcinomas compared to matched normal lung tissues and in lung tumor cell lines by mechanisms not exclusive to copy number gain. Upon loss of CLPTM1L accumulation in lung tumor cells, cisplatin and camptothecin induced apoptosis were increased in direct proportion to the level of CLPTM1L knockdown. Bcl-xL accumulation was significantly decreased upon loss of CLPTM1L. Expression of exogenous Bcl-xL abolished sensitization to apoptotic killing with CLPTM1L knockdown. These results demonstrate that CLPTM1L, an overexpressed protein in lung tumor cells, protects from genotoxic stress induced apoptosis through regulation of Bcl-xL. Thus, this study implicates anti-apoptotic CLPTM1L function as a potential mechanism of susceptibility to lung tumorigenesis and resistance to chemotherapy.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Article number

e36116

Journal (Volume, Issue Number)

PloS one (Volume 7, Issue 6)

Publication milestones

  • Published - 06/04/2012

Publication status

Published - 06/04/2012

ISSN

1932-6203

Publication IDs

  • Scopus: 84861899749
  • PubMed: 22675468

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Mentions
1
Captures
50
Citation count
95

Funding Details

We would like to thank Julie DiMitry for assistance with flow cytometry experiments as well as Peter Vedell and Pengyuan Liu for advice on statistical methods. We would like to thank Haris Vikis and Jay Tichelaar for their discussion and comments on the manuscript. We thank the Tissue Procurement Core at Washington University and the Siteman Cancer Center for providing patient RNA and DNA samples, and the Human Protein Atlas project, funded by the Knut and Alice Wallenberg Foundation, for compiling protein expression profiles and annotated IHC images.
FundersFunding number
NCI
U19CA148127
UW
-
Alvin J. Siteman Cancer Center
-
Knut och Alice Wallenbergs Stiftelse
-